Trial Profile
A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs HH-CYH33 (Primary)
- Indications Advanced breast cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Haihe Biopharma; ShangHai HaiHe Pharmaceutical
- 04 Jan 2023 Planned End Date changed from 20 Aug 2021 to 31 Mar 2024.
- 04 Jan 2023 Planned primary completion date changed from 20 Apr 2021 to 30 Jun 2023.
- 02 Mar 2021 Results (n=39; data cutoff date: 31 Oct 2020) presented at the 19th International Congress on Targeted Anticancer Therapies